MCF Advisors LLC Invests $68,000 in Cencora, Inc. (NYSE:COR)

MCF Advisors LLC purchased a new stake in shares of Cencora, Inc. (NYSE:COR) during the 1st quarter, Holdings Channel reports. The fund purchased 280 shares of the company’s stock, valued at approximately $68,000.

A number of other institutional investors have also added to or reduced their stakes in COR. Vanguard Group Inc. bought a new stake in shares of Cencora during the fourth quarter worth $4,212,508,000. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Cencora during the 1st quarter valued at $66,911,000. PNC Financial Services Group Inc. bought a new stake in Cencora during the 4th quarter worth $51,339,000. Los Angeles Capital Management LLC acquired a new position in Cencora in the 1st quarter worth about $45,692,000. Finally, Pensioenfonds Rail & OV bought a new position in Cencora in the first quarter valued at about $37,371,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Price Performance

Shares of NYSE COR opened at $225.30 on Friday. The company has a quick ratio of 0.53, a current ratio of 0.89 and a debt-to-equity ratio of 3.41. The company has a market capitalization of $44.94 billion, a PE ratio of 24.65, a P/E/G ratio of 1.58 and a beta of 0.48. The firm has a fifty day simple moving average of $229.12 and a 200 day simple moving average of $227.99. Cencora, Inc. has a twelve month low of $171.65 and a twelve month high of $246.75.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, May 1st. The company reported $3.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.65 by $0.15. Cencora had a return on equity of 268.67% and a net margin of 0.67%. The company had revenue of $68.41 billion for the quarter, compared to the consensus estimate of $70.60 billion. During the same period in the previous year, the business earned $3.50 EPS. The firm’s revenue was up 7.8% compared to the same quarter last year. On average, sell-side analysts forecast that Cencora, Inc. will post 13.44 EPS for the current year.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, May 24th. Investors of record on Friday, May 10th were given a dividend of $0.51 per share. The ex-dividend date of this dividend was Thursday, May 9th. This represents a $2.04 dividend on an annualized basis and a dividend yield of 0.91%. Cencora’s payout ratio is presently 22.32%.

Analyst Upgrades and Downgrades

COR has been the topic of several research reports. StockNews.com cut Cencora from a “strong-buy” rating to a “buy” rating in a report on Thursday, May 2nd. Robert W. Baird upped their price target on shares of Cencora from $275.00 to $277.00 and gave the company an “outperform” rating in a research report on Thursday, May 2nd. Citigroup raised their price target on shares of Cencora from $265.00 to $280.00 and gave the company a “buy” rating in a research note on Tuesday, April 30th. Finally, SVB Leerink reissued an “outperform” rating and issued a $275.00 price objective on shares of Cencora in a research note on Thursday. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $235.30.

Insider Activity at Cencora

In other Cencora news, CEO Steven H. Collis sold 10,754 shares of Cencora stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $237.48, for a total value of $2,553,859.92. Following the completion of the sale, the chief executive officer now directly owns 285,088 shares of the company’s stock, valued at $67,702,698.24. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Cencora news, CEO Steven H. Collis sold 10,754 shares of the firm’s stock in a transaction that occurred on Tuesday, April 16th. The stock was sold at an average price of $237.48, for a total value of $2,553,859.92. Following the completion of the sale, the chief executive officer now owns 285,088 shares of the company’s stock, valued at $67,702,698.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Walgreens Boots Alliance, Inc. sold 1,859,390 shares of the business’s stock in a transaction that occurred on Wednesday, May 22nd. The shares were sold at an average price of $215.12, for a total value of $399,991,976.80. Following the sale, the insider now owns 24,418,171 shares of the company’s stock, valued at approximately $5,252,836,945.52. The disclosure for this sale can be found here. Insiders have sold 1,956,675 shares of company stock worth $422,352,056 in the last quarter. Company insiders own 15.80% of the company’s stock.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.